HIV / AIDS in the News

EACS 2025: Doxy-PEP Cuts Chlamydia and Syphilis Risk in Men Living With HIV - European Medical Journal

 

HIV: Campaigners call for introduction of 'game-changing' drug - BBC

 

A Look at Gilead Sciences’s Valuation Following Breakthrough HIV and Cancer Clinical Trial Results - Yahoo

 

A Look at Gilead Sciences’s Valuation Following Breakthrough HIV and Cancer Clinical Trial Results - Yahoo Finance

 

Amazing People of 2025: Javier Muñoz - hivplusmag.com

 

N6LS bNAb HIV Treatment - Infectious Disease Special Edition

 

HIVMA HIV Research IDWeek 2025 Anna Person - Infectious Disease Special Edition

 

Study Finds Patients Prefer 1 HIV Long-Acting Injectable Due to Fewer Injection Site Reactions - Infectious Disease Special Edition

 

European standards of HIV prevention and care: Module on Commencement of antiretroviral therapy - European Centre for Disease Prevention and Control

 

Doravirine Islatravir HIV Treatment - Infectious Disease Special Edition

 

Cutaneous Squamous Cell Carcinoma Mimicking Kaposi Sarcoma in an HIV-Positive Patient: Diagnostic Challenges and Therapeutic Response to Liposomal Doxorubicin - Cureus

 

Novel HIV Combo Therapy of Lenacapavir and 2 bNAbs Found Effective, Well Tolerated in Phase 2 Trial - Infectious Disease Special Edition

 

From HIV to Global Cancer Prevention: A New Chapter in Global Health Financing - amfAR, The Foundation for AIDS Research

 

Gilead Sciences: HIV Treatments Propel Stocks - StocksToTrade

 

An injection to prevent HIV is something to celebrate - The Observer

 

UK's NICE Recommends ViiV Healthcare’s Injectable HIV Treatment - GSK (NYSE:GSK) - Benzinga

 

NICE recommends HIV prevention injection for people unable to take oral PrEP - The Pharmaceutical Journal

 

HIV Updates Put Comorbidities First — ART on Cruise Control - Medscape

 

UCF Team Advances Low-Cost Multiplex RNA Test for HIV, HBV, and HCV - Contagion Live

 

Investigational HIV bNAb N6LS Shown Safe, Tolerable in Phase 2b Trial - Infectious Disease Special Edition

 

Islatravir Lenacapavir HIV Treatment - Infectious Disease Special Edition

 

Islatravir Lenacapavir HIV Treatment - Infectious Disease Special Edition

 

ViiV Secures English Funding For First Long-Acting HIV Prevention Injection - insights.citeline.com

 

ViiV’s bi-monthly HIV injection approved by NICE - European Medical Journal

 

NHS to roll out first long-acting injection to prevent HIV - Wired-Gov

 

Record numbers accessing HIV prevention treatment | National Institute for Health and Clinical Excellence (NICE) - Wired-Gov

 

EACS 2025: Over Half of HIV Diagnoses in Migrants Occur Years Post-Migration - European Medical Journal

 

US aid cuts severely undermine Senegal’s fight against HIV - EL PAÍS English

 

NICE Endorses UK’s First Injectable PrEP to Curb HIV - Medscape

 

ViiV's bimonthly HIV PrEP jab cleared for use by NHS - pharmaphorum